ID   PA-1
AC   CVCL_0479
SY   PA1; PA I; PAI
DR   BTO; BTO:0001591
DR   CLO; CLO_0008350
DR   EFO; EFO_0006465
DR   MCCL; MCC:0000377
DR   CLDB; cl3856
DR   CLDB; cl3857
DR   CLDB; cl3858
DR   CLDB; cl3859
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-1572
DR   BCRC; 60063
DR   BioSample; SAMN01821586
DR   BioSample; SAMN03473209
DR   BioSample; SAMN03472415
DR   CCLE; PA1_OVARY
DR   CCRID; 3111C0001CCC000021
DR   Cell_Model_Passport; SIDM01140
DR   CGH-DB; 9358-4
DR   ChEMBL-Cells; CHEMBL3308812
DR   ChEMBL-Targets; CHEMBL614949
DR   CLS; 300402/p655_PA-1
DR   Cosmic; 688112
DR   Cosmic; 801353
DR   Cosmic; 809111
DR   Cosmic; 844343
DR   Cosmic; 909255
DR   Cosmic; 931368
DR   Cosmic; 1305331
DR   Cosmic; 1995610
DR   Cosmic-CLP; 909255
DR   DepMap; ACH-001374
DR   ECACC; 90013101
DR   GDSC; 909255
DR   GEO; GSM186444
DR   GEO; GSM186445
DR   GEO; GSM784566
DR   GEO; GSM1374804
DR   GEO; GSM1670330
DR   IARC_TP53; 1418
DR   IARC_TP53; 8338
DR   ICLC; HTL97002
DR   IZSLER; BS TCL 179
DR   JCRB; JCRB9061
DR   LINCS_LDP; LCL-1416
DR   PharmacoDB; PA1_1235_2019
DR   RCB; RCB1946
DR   TKG; TKG 0573
DR   Wikidata; Q54937331
RX   DOI=10.11418/jtca1981.16.3_173;
RX   PubMed=2653399;
RX   PubMed=6740333;
RX   PubMed=6931103;
RX   PubMed=9290701;
RX   PubMed=9359923;
RX   PubMed=9698466;
RX   PubMed=11314036;
RX   PubMed=11330945;
RX   PubMed=10567668;
RX   PubMed=15677628;
RX   PubMed=16080959;
RX   PubMed=20164919;
RX   PubMed=22710073;
RX   PubMed=23415752;
RX   PubMed=25485619;
RX   PubMed=27397505;
RX   PubMed=30894373;
WW   http://www.cellresource.cn/fdetail.aspx?id=21
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Part of: KuDOS 95 cell line panel.
CC   Doubling time: 36 hours (PubMed=2653399); 22.77 hours (https://www.synapse.org/#!Synapse:syn2347014).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Heterozygous for NRAS p.Gly12Asp (c.35G>A); not found in early passages (PubMed=6740333).
CC   Sequence variation: Heterozygous for TP53 p.Pro316Pro (c.948C>T) (Cosmic-CLP).
CC   Omics: Deep exome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=21.08%; Native American=17.69%; East Asian, North=1.54%; East Asian, South=0.7%; South Asian=0.4%; European, North=26.01%; European, South=32.58% (PubMed=30894373).
CC   Caution: TP53 mutation indicated to be at p.Asn239Asp (c.715A>G) in DOI=10.11418/jtca1981.16.3_173 and PubMed=9359923.
CC   Discontinued: RCB; RCB1946; true.
CC   Discontinued: TKG; TKG 0573; true.
CC   Derived from metastatic site: Ascites.
ST   Source(s): ATCC; CCRID; CLS; COG; Cosmic-CLP; ECACC; JCRB; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 9,12
ST   D13S317: 9,10 (ATCC; CCRID; CLS; COG; Cosmic-CLP; ECACC; PubMed=25877200)
ST   D13S317: 9,10,13 (JCRB)
ST   D16S539: 9,12 (ATCC; CCRID; COG; Cosmic-CLP; ECACC; JCRB; PubMed=25877200)
ST   D16S539: 9 (CLS)
ST   D18S51: 15,18
ST   D19S433: 13
ST   D21S11: 29,31.2
ST   D2S1338: 24
ST   D3S1358: 15
ST   D5S818: 11
ST   D7S820: 9
ST   D8S1179: 14,15
ST   FGA: 24
ST   Penta D: 9,12
ST   Penta E: 14,20
ST   TH01: 7,9
ST   TPOX: 11
ST   vWA: 15,17
DI   NCIt; C8814; Ovarian mixed germ cell tumor
DI   ORDO; Orphanet_180234; Mixed germ cell tumor
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Female
AG   12Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 12-03-20; Version: 32
//
RX   DOI=10.11418/jtca1981.16.3_173;
RA   Mihara K., Miyazaki M., Fushimi K., Tsuji T., Inoue Y., Fukaya K.-I.,
RA   Ohashi R., Namba M.;
RT   "The p53 gene status and other cellular characteristics of human cell
RT   lines maintained in our laboratory.";
RL   Tissue Cult. Res. Commun. 16:173-178(1997).
//
RX   PubMed=2653399; DOI=10.1038/bjc.1989.108;
RA   Hills C.A., Kelland L.R., Abel G., Siracky J., Wilson A.P.,
RA   Harrap K.R.;
RT   "Biological properties of ten human ovarian carcinoma cell lines:
RT   calibration in vitro against four platinum complexes.";
RL   Br. J. Cancer 59:527-534(1989).
//
RX   PubMed=6740333; DOI=10.1126/science.6740333;
RA   Tainsky M.A., Cooper C.S., Giovanella B.C., Vande Woude G.F.;
RT   "An activated rasN gene: detected in late but not early passage human
RT   PA1 teratocarcinoma cells.";
RL   Science 225:643-645(1984).
//
RX   PubMed=6931103; DOI=10.1002/ijc.2910250104;
RA   Zeuthen J., Norgaard J.O.R., Avner P., Fellous M., Wartiovaara J.,
RA   Vaheri A., Rosen A., Giovanella B.C.;
RT   "Characterization of a human ovarian teratocarcinoma-derived cell
RT   line.";
RL   Int. J. Cancer 25:19-32(1980).
//
RX   PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D;
RA   Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T.,
RA   Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M.,
RA   Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.;
RT   "Screening the p53 status of human cell lines using a yeast functional
RT   assay.";
RL   Mol. Carcinog. 19:243-253(1997).
//
RX   PubMed=9359923; DOI=10.18926/AMO/30789;
RA   Mihara K., Miyazaki M., Kondo T., Fushimi K., Tsuji T., Inoue Y.,
RA   Fukaya K.-I., Ishioka C., Namba M.;
RT   "Yeast functional assay of the p53 gene status in human cell lines
RT   maintained in our laboratory.";
RL   Acta Med. Okayama 51:261-265(1997).
//
RX   PubMed=9698466; DOI=10.1006/gyno.1998.5039;
RA   Maxwell G.L., Risinger J.I., Tong B., Shaw H., Barrett J.C.,
RA   Berchuck A., Futreal P.A.;
RT   "Mutation of the PTEN tumor suppressor gene is not a feature of
RT   ovarian cancers.";
RL   Gynecol. Oncol. 70:13-16(1998).
//
RX   PubMed=11314036; DOI=10.1038/sj.onc.1204211;
RA   Forgacs E., Wren J.D., Kamibayashi C., Kondo M., Xu X.L.,
RA   Markowitz S.D., Tomlinson G.E., Muller C.Y., Gazdar A.F., Garner H.R.,
RA   Minna J.D.;
RT   "Searching for microsatellite mutations in coding regions in lung,
RT   breast, ovarian and colorectal cancers.";
RL   Oncogene 20:1005-1009(2001).
//
RX   PubMed=11330945; DOI=10.1006/gyno.2001.6132;
RA   Watanabe T., Imoto I., Kosugi Y., Ishiwata I., Inoue S., Takayama M.,
RA   Sato A., Inazawa J.;
RT   "A novel amplification at 17q21-23 in ovarian cancer cell lines
RT   detected by comparative genomic hybridization.";
RL   Gynecol. Oncol. 81:172-177(2001).
//
RX   PubMed=10567668; DOI=10.3892/ijmm.4.6.597;
RA   Gao C., Miyazaki M., Li J.W., Tsuji T., Inoue Y., Namba M.;
RT   "Cytogenetic characteristics and p53 gene status of human
RT   teratocarcinoma PA-1 cells in 407-445 passages.";
RL   Int. J. Mol. Med. 4:597-600(1999).
//
RX   PubMed=15677628; DOI=10.1093/carcin/bgi032;
RA   Gorringe K.L., Chin S.-F., Pharoah P., Staines J.M., Oliveira C.,
RA   Edwards P.A.W., Caldas C.;
RT   "Evidence that both genetic instability and selection contribute to
RT   the accumulation of chromosome alterations in cancer.";
RL   Carcinogenesis 26:923-930(2005).
//
RX   PubMed=16080959; DOI=10.1016/j.cancergencyto.2005.01.003;
RA   Sarraf S., Tejada R., Abawi M., Oberst M., Dennis T., Simon K.C.,
RA   Blancato J.;
RT   "The human ovarian teratocarcinoma cell line PA-1 demonstrates a
RT   single translocation: analysis with fluorescence in situ
RT   hybridization, spectral karyotyping, and bacterial artificial
RT   chromosome microarray.";
RL   Cancer Genet. Cytogenet. 161:63-69(2005).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=22710073; DOI=10.1016/j.ygyno.2012.06.017;
RA   Korch C., Spillman M.A., Jackson T.A., Jacobsen B.M., Murphy S.K.,
RA   Lessey B.A., Jordan V.C., Bradford A.P.;
RT   "DNA profiling analysis of endometrial and ovarian cell lines reveals
RT   misidentification, redundancy and contamination.";
RL   Gynecol. Oncol. 127:241-248(2012).
//
RX   PubMed=23415752; DOI=10.1016/j.molonc.2012.12.007;
RA   Stordal B., Timms K., Farrelly A., Gallagher D., Busschots S.,
RA   Renaud M., Thery J., Williams D., Potter J., Tran T., Korpanty G.,
RA   Cremona M., Carey M.S., Li J., Li Y., Aslan O., O'Leary J.J.,
RA   Mills G.B., Hennessy B.T.;
RT   "BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one
RT   functionally deleterious BRCA1 mutation.";
RL   Mol. Oncol. 7:567-579(2013).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H.,
RA   Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y.,
RA   Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D.,
RA   Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D.,
RA   Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S.,
RA   Zhang Z.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//